Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1261-1280 of 2,120 trials

B-Cell Non-Hodgkin Lymphoma: BI-1206 Treatment Study

We are studying a new monoclonal antibody combined with rituximab, with or without acalabrutinib, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to assess safety and how well it may work in reducing cancer cells.

Indolent B-Cell Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Esophageal Adenocarcinoma: The PRESTO Trial

We are studying a combination of durvalumab and chemoradiation to see if it can help preserve the esophagus in patients with early-stage cancer. This trial aims to avoid surgery and assess treatment effectiveness and safety.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: Telisotuzumab Adizutecan Study

We are investigating a new treatment combination for people with metastatic colorectal cancer to see if it works better and is safer than current standard treatments.

Metastatic Colorectal Cancer≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Gastric Cancer: New Drug Combinations

We are studying whether a new combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is more effective than standard treatment for patients with advanced gastric or esophageal cancer. The goal is to improve survival and quality of life for those with HER2 negative cancer.

HER2 Negative Gastric CancerEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Targeted Therapies for Moderate to Severe Crohn’s Disease

We are studying new targeted treatments for adults with moderate to severe Crohn’s disease. The goal is to evaluate their safety and effectiveness in managing this condition.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Juvenile Idiopathic Arthritis: MOVE-JIA Trial

We are comparing two treatment withdrawal strategies for children and adolescents with Juvenile Idiopathic Arthritis in remission. The goal is to see which method better prevents disease flares compared to ongoing stable treatment.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Major Depression: Samyr Injection Study

We are testing whether Samyr, an injectable treatment, can improve symptoms in people with major depression who are not responding well to their current antidepressants. This study compares Samyr to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesPsychiatry

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

NY-ESO-1 T-Cells for Synovial Sarcoma and Liposarcoma

We are studying genetically engineered T cells in patients with synovial sarcoma and myxoid/round cell liposarcoma. The goal is to see if this treatment is effective and safe for those with specific tumor markers.

Myxoid and Round Cell LiposarcomaSynovial SarcomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Long-Term Follow-Up of Adoptive Cell Therapies

We are monitoring individuals who received genetically modified cell treatments to check for any delayed side effects and how long these cells remain in the body. This study aims to ensure safety and understand the treatment's long-term effects.

Myxoid LiposarcomaMultiple MyelomaSynovial Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Allopurinol for Brain Protection in Newborns with Heart Disease

We are studying whether allopurinol can help reduce brain injury in newborns with critical congenital heart disease during and after cardiac surgery. This trial will also assess its effects on brain and heart function, as well as overall development.

Brain Injury in Neonates with Congenital Heart Disease>2 yearsConfirmation phase (III)Standard MedicinesCardiologyNeurologyPediatrics

Crohn's Disease: RO7790121 Treatment Study

We are evaluating a new treatment for people with moderately to severely active Crohn's disease to see if it helps improve symptoms and quality of life compared to a placebo.

Moderately to Severely Active Crohn's DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Frozen Shoulder Treatment: Corticosteroid Injection with Nerve Block

We are studying whether a corticosteroid injection combined with a nerve block provides better pain relief and shoulder function than an injection with a placebo. This trial aims to help improve treatment strategies for patients with Frozen Shoulder.

Frozen ShoulderAdhesive Capsulitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesOrthopedics and Traumatology

HPV Vaccination After Cervical Lesion Treatment

We are studying whether a secondary HPV vaccination helps women over 45 who have been treated for high-grade cervical lesions achieve HPV-negative status and reduce the risk of recurrence or cancer.

High-Grade Cervical Intraepithelial Lesions>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Acute Myeloid Leukemia: Sulfasalazine with Chemotherapy

We are studying the addition of sulfasalazine to standard chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. The goal is to evaluate safety and effectiveness compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Metastatic Non-Small Cell Lung Cancer: Ivonescimab vs Pembrolizumab

We are studying whether ivonescimab combined with chemotherapy helps patients with metastatic non-small cell lung cancer live longer and manage their disease better than pembrolizumab with chemotherapy.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

MEN1703 for Aggressive B-cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of MEN1703 alone and with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. This research aims to find better treatment options for this challenging cancer.

Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology